阿托伐他汀对健康志愿者23价肺炎球菌多糖疫苗体液免疫应答的影响:StatVax随机临床试验
StatVax双盲安慰剂对照随机试验纳入22名未接种过肺炎球菌疫苗的健康志愿者,随机接受28天阿托伐他汀40mg或乳糖安慰剂,第7天肌注Pneumovax 23。结论认为阿托伐他汀可增强对T细胞非依赖性肺炎疫苗接种的抗原特异性初级体液免疫应答。
要点
- 阿托伐他汀组接种后21天总抗肺炎球菌抗体滴度从基线均值32.58μg/mL升至147.7μg/mL。
- 安慰剂组接种后21天总抗肺炎球菌抗体滴度从基线均值30.81μg/mL升至104.4μg/mL。
核心结论
- 阿托伐他汀增强健康志愿者对23价肺炎球菌多糖疫苗的抗原特异性初级体液免疫应答。
- 需更大规模目标人群队列研究确认后,围疫苗接种期常规剂量他汀可能成为低免疫原性多糖疫苗的新型佐剂。
研究设计与样本
- 双盲、安慰剂对照、单中心随机临床试验(StatVax),2014年6月至7月入组,随访至2014年9月。
- 22名无既往肺炎球菌疫苗接种史的健康志愿者完成研究,随机接受28天阿托伐他汀40mg(n=12)或匹配乳糖安慰剂(n=10)。
- 治疗第7天肌内注射Pneumovax 23;主要结局为接种后总肺炎球菌特异性抗体滴度相对基线的倍数变化。
主要发现
- 阿托伐他汀组总抗肺炎球菌抗体滴度从基线均值32.58(SD 15.96)μg/mL升至接种后21天147.7(SD 71.52)μg/mL。
- 安慰剂组总抗肺炎球菌抗体滴度从基线均值30.81(SD 13.04)μg/mL升至接种后21天104.4(SD 45)μg/mL。
- 22名随机参与者平均年龄23.86岁(SD 4.121),女性11名(50%),均完成试验。
临床怎么用
- 围疫苗接种期常规剂量他汀可能作为低免疫原性多糖疫苗佐剂的候选策略,但须待更大规模目标人群研究确认。
局限性
- 样本量小(22名健康志愿者完成研究),结论需更大规模目标人群队列研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysaccharide vaccination. METHODS: Double-blind, placebo-controlled, single-center randomized clinical trial entitled StatVax. Subjects were enrolled between June and July 2014 and followed up through September 2014. 33 healthy volunteers signed informed consent after volunteer sampling. 11 participants were excluded; 22 healthy volunteers without prior pneumococcal vaccination were enrolled and completed the study. Participants were randomized to receive a 28-day course of 40 mg atorvastatin (n = 12) or matching lactose placebo (n = 10). On day 7 of treatment, Pneumovax 23 was administered intramuscularly. The primary outcome was fold change in total pneumococcal-specific antibody titer determined by a ratio of post-vaccination titer over baseline titer. Secondary outcomes included serotype-specific pneumococcal antibody titer, seroconversion, complete blood counts (CBC), erythrocyte sedimentation rate (ESR), and serum cytokine analysis. RESULTS: Of the 22 randomized patients (mean age, 23.86; SD, 4.121; 11 women [50%]), 22 completed the trial. Total anti-pneumococcal antibody titer in the atorvastatin group went from a baseline mean of 32.58 (SD, 15.96) to 147.7 (SD, 71.52) μg/mL at 21 days post-vaccination while titer in the placebo group went from a mean of 30.81 (SD, 13.04) to 104.4 (SD, 45) μg/mL. When comparing fold change between treatment groups, there was a significant increase in fold change of total anti-pneumococcal antibody titer in the atorvastatin group compared to the placebo group (2-way ANOVA, p = .0177). CONCLUSIONS: Atorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02097589.
引用
- Wildes TJ, Grippin A, Fasanya H, et al. Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial. Vaccine. 2019. PMID: 30686636. doi:10.1016/j.vaccine.2019.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。